The AJCC 8th Edition Breast Cancer Staging System specifies that the presence of ≥1 CTC per 7.5 mL in early-stage breast cancer patients indicates a poor prognosis. Domestic research teams have further validated that baseline and post-treatment CTC levels can predict outcomes in advanced breast cancer patients.
Learn More >
Circulating Tumor Cells (CTCs) can be used as an auxiliary tool for clinical tumor prognosis assessment and hold certain reference value in efficacy monitoring, drug resistance evaluation, and treatment guidance
Learn More >
CTC technology, recognized as one of the most promising liquid biopsy approaches, has garnered worldwide expert consensus and guideline endorsements, supported by over 20,000 research publications and established clinical applications across major cancer types.
Learn More >
